Sizling Stock Update: Amicus Therapeutics inc (NASDAQ:FOLD)

26

Amicus Therapeutics inc (NASDAQ:FOLD) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.

Amicus Therapeutics inc (NASDAQ:FOLD) lost -0.92 Percent and closed its previous trading session at $15.11. The stock traded with the average Volume of 2.17 Million at the end of last session.

Amicus Therapeutics inc (NASDAQ:FOLD) has the Market Capitalization of 2.93 Billion. The Stock has its 52-week High of $17.62 and 52-Week Low of $11.44 and it touched its 52-week high on 06/20/18 and 52-Week Low on 08/11/17

.

The company reported its last earnings Actual EPS of $-0.33/share. While, the analyst predicted that the company could provide an EPS of $-0.33/share.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -1.17% where SMA50 and SMA200 are -4.42% and 2.15% respectively.

The company shows its Return on Assets (ROA) value of -35.8%. The Return on Equity (ROE) value stands at -71.9%. While it’s Return on Investment (ROI) value is -21.7%.

Amicus Therapeutics inc (NASDAQ:FOLD) currently has a Weekly Volatility of 5.45% percent while its Monthly Volatility is at 4.08% percent. While talking about Performance of the Stock, Amicus Therapeutics inc currently has a Weekly performance of 3.35%, monthly performance percentage is -8.03 percent, Quarterly performance is 8.94 percent, 6 months performance shows a percent value of 1.58% and Yearly Performance is 20.11 percent.

Company Profile:

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

SHARE